STAT March 9, 2023
Ben Brody

The Food and Drug Administration is considering whether it needs to revamp guidance on how FDA-regulated manufacturers should deal with online misinformation about their products as the agency continues to contend with a deadly tide of falsehoods spreading on social media, Commissioner Robert Califf told STAT.

In an interview, FDA Commissioner Robert Califf said the agency is grappling with how best to handle an explosion of misinformation, including vaccine skepticism that has worsened the toll of Covid-19 pandemic. While the agency is considering whether it can take on misinformation more head-on, he said the FDA might well be able to find a clear path to better support drug, vaccine, and device makers whose products are the targets of misinformation.

“Let’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Healthcare System, Public Health / COVID, Social Media, Technology
Related Articles:
FDA approves clinical trials for pig organ transplants
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
FDA Approves Third Tocilizumab Biosimilar
The Biden Administration’s Swan Song on Digital Health: Two FDA Guidances on Artificial Intelligence and FDA’s Defense of its Clinical Decision Support Guidance
FDA warns GLP-1 compounder over safety rules

Share This Article